RecruitingPHASE1, PHASE2NCT06097832

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

Studying AL amyloidosis

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Nexcella Inc.
Intervention: NXC-201 CAR-T(biological)
Enrollment: 40 enrolled
Eligibility: 18-120 years · All sexes
Timeline: 2024 – 2039

Study locations (18)

Sutter Health Alta Bates, Berkeley, California, United States
City of Hope, Duarte, California, United States
University of California Los Angeles, Los Angeles, California, United States
University of California Davis Medical Center, Sacramento, California, United States
Stanford University, Stanford, California, United States
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
The University of Kansas Cancer Center, Fairway, Kansas, United States
Tufts Medical Center, Boston, Massachusetts, United States
Boston University Medical Center, Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Washington University Siteman Cancer Center, St Louis, Missouri, United States
Memorial Sloan Kettering Comprehensive Cancer Center, New York, New York, United States
University of Cincinnati Cancer Center, Cincinnati, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
+3 more locations on ClinicalTrials.gov

Collaborators

Immix Biopharma, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06097832 on ClinicalTrials.gov

Other trials for AL amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for AL amyloidosis →

← Back to all trials